Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to baseline risk in PARADIGM-HF

被引：0

作者：

Simpson, J. ^{[1
]}

Squire, I. B. ^{[2
]}

Martinez, F. ^{[3
]}

Rouleau, J. L. ^{[4
]}

Swedberg, K. ^{[5
]}

Zile, M. ^{[6
]}

Lefkowitz, M. ^{[7
]}

Packer, M. ^{[8
]}

Mcmurray, J. J. V. ^{[1
]}

Solomon, S. D. ^{[9
]}

机构：

[1] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow, Lanark, Scotland

[2] NIHR Biomed Res Unit Cardiovasc Dis, Leicester, Leics, England

[3] Univ Nacl Cordoba, Med Interna, Inst DAMIC, Fdn Rusculleda, RA-5000 Cordoba, Argentina

[4] Univ Montreal, Montreal, PQ, Canada

[5] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden

[6] Med Univ S Carolina, Charleston, SC 29425 USA

[7] Novartis Pharmaceut, Hanover, NH USA

[8] Univ Texas Southwestern Med Sch, Dallas, TX USA

[9] Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2015年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P1416

引用

页码：295 / 296

页数：2

共 50 条

[31] Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome
Li, Ying
Kang, Li
Rong, Kai
Zhang, Yue
Suo, Ya
Yuan, Meng
Bao, Qiankun
Shao, Shuai
Tse, Gary
Li, Rong
Liu, Tong
Li, Guangping
LIFE SCIENCES, 2021, 280
[32] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF LCZ696, A NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI)
Gu, J.
Noe, A.
Chandra, R.
Al-Fayoumi, S.
Ligueros, M.
Sarangapani, R.
Maahs, S.
Ksander, G.
Rigel, D.
Jeng, A.
Dole, W.
JOURNAL OF HYPERTENSION, 2009, 27 : S9 - S9
[33] The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
Chen, Yan
He, Qian
Mo, Dun-Chang
Chen, Long
Lu, Jia-Lu
Li, Rui-Xing
Huang, Jie
MEDICINE, 2022, 101 (41) : E30904
[34] Comparative efficacy of valsartan and LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in hypertensive individuals: effects of gender
Ruilope, L. M.
Izzo, J. L., Jr.
Conde, L. G.
Zappe, D. H.
Zhang, Y.
Zhang, J.
EUROPEAN HEART JOURNAL, 2014, 35 : 571 - 571
[35] The angiotensin receptor neprilysin inhibitor LCZ696 improves systolic cardiac function compared to angiotensin converting enzyme inhibition in a rat model of myocardial infarction
Kompa, A. R.
Weller, T. J.
Von Lueder, T.
Wang, B. H.
Krum, H.
EUROPEAN HEART JOURNAL, 2015, 36 : 661 - 661
[36] A metabolomics approach to profiling the cardioprotective effect of LCZ696, an angiotensin receptor-neprilysin inhibitor, on ischemia induced heart failure
Xia, Yan
Chen, Zhangwei
Chen, Ao
Lu, Danbo
Jia, Jianguo
Zou, Yunzeng
Qian, Juying
Ge, Junbo
RSC ADVANCES, 2017, 7 (46) : 29170 - 29183
[37] LCZ696, the First-in-Class Angiotensin Receptor Neprilysin Inhibitor, Improves Vascular Reactivity in the Setting of Heart Failure
Trivedi, Rishi K.
Li, Zhen
Polhemus, David J.
Yoo, Daniel
Koiwaya, Hiroshi
Goodchild, Traci T.
Lefer, David J.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 112 : 162 - 162
[38] The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats
Rahman, Asadur
Sherajee, Shamshad J.
Rafiq, Kazi
Kobara, Hideki
Masaki, Tsutomu
Nakano, Daisuke
Morikawa, Takashi
Konishi, Yoshio
Imanishi, Masahito
Nishiyama, Akira
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2020, 142 (03) : 124 - 126
[39] Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats
Miyoshi, Toru
Nakamura, Kazufumi
Miura, Daiji
Yoshida, Masashi
Saito, Yukihiro
Akagi, Satoshi
Ohno, Yuko
Kondo, Megumi
Ito, Hiroshi
CARDIOLOGY JOURNAL, 2019, 26 (05) : 575 - 583
[40] Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial
Lucchese B.
Nature Reviews Nephrology, 2010, 6 (7) : 383 - 383

← 1 2 3 4 5 →